The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

Ischaemic Stroke ◽

Acute Ischaemic Stroke ◽

Controlled Trial ◽

The Third ◽

Tissue Plasminogen ◽

Randomised Controlled ◽

Faculty Opinions recommendation of The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717297826.793153377 ◽

2012 ◽

Author(s):

Mark Wainwright

Keyword(s):

Ischaemic Stroke ◽

Acute Ischaemic Stroke ◽

Controlled Trial ◽

The Third ◽

Tissue Plasminogen ◽

Randomised Controlled ◽

Faculty Opinions recommendation of The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717297826.792652833 ◽

2012 ◽

Author(s):

Harri Jenkins

Keyword(s):

Ischaemic Stroke ◽

Acute Ischaemic Stroke ◽

Controlled Trial ◽

The Third ◽

Tissue Plasminogen ◽

Randomised Controlled ◽

Faculty Opinions recommendation of The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717297826.793453717 ◽

2012 ◽

Author(s):

Shyam Prabhakaran ◽

Laurel J Smit

Keyword(s):

Ischaemic Stroke ◽

Acute Ischaemic Stroke ◽

Controlled Trial ◽

The Third ◽

Tissue Plasminogen ◽

Randomised Controlled ◽

Faculty Opinions recommendation of The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717297826.793152901 ◽

2012 ◽

Author(s):

Todd Allen

Keyword(s):

Ischaemic Stroke ◽

Acute Ischaemic Stroke ◽

Controlled Trial ◽

The Third ◽

Tissue Plasminogen ◽

Randomised Controlled ◽

Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial

The Lancet Neurology ◽

10.1016/s1474-4422(13)70130-3 ◽

2013 ◽

Vol 12 (8) ◽

pp. 768-776 ◽

Cited By ~ 85

Keyword(s):

Ischaemic Stroke ◽

Acute Ischaemic Stroke ◽

Controlled Trial ◽

Long Term Outcomes ◽

The Third ◽

Randomised Controlled ◽

Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial

The Lancet Neurology ◽

10.1016/s1474-4422(15)00012-5 ◽

2015 ◽

Vol 14 (5) ◽

pp. 485-496 ◽

Cited By ~ 90

Keyword(s):

Ischaemic Stroke ◽

Acute Ischaemic Stroke ◽

Controlled Trial ◽

Secondary Analysis ◽

The Third ◽

Intravenous Alteplase ◽

Randomised Controlled ◽

Imaging Signs ◽

The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke

BMC Neurology ◽

10.1186/1471-2377-14-106 ◽

2014 ◽

Vol 14 (1) ◽

Cited By ~ 25

Author(s):

Nicola Logallo ◽

Christopher E Kvistad ◽

Aliona Nacu ◽

Halvor Naess ◽

Ulrike Waje-Andreassen ◽

...

Keyword(s):

Ischaemic Stroke ◽

Acute Ischaemic Stroke ◽

Controlled Trial ◽

Randomised Controlled ◽

Faculty Opinions recommendation of Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1168144.630276 ◽

2009 ◽

Author(s):

David Liebeskind

Keyword(s):

Ischaemic Stroke ◽

Acute Ischaemic Stroke ◽

Subgroup Analysis ◽

Controlled Trial ◽

Stroke Treatment ◽

Randomised Controlled

Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism

Journal of Vascular Surgery ◽

10.1016/0741-5214(89)90460-6 ◽

1989 ◽

Vol 10 (3) ◽

pp. 362

Author(s):

Patrick J. O'Hara

Keyword(s):

Pulmonary Embolism ◽

Plasminogen Activator ◽

Tissue Plasminogen Activator ◽

Acute Pulmonary Embolism ◽

Controlled Trial ◽

Tissue Plasminogen ◽

Randomised Controlled

Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke

The Lancet ◽

10.1016/s0140-6736(95)92049-8 ◽

1995 ◽

Vol 346 (8989) ◽

pp. 1509-1514 ◽

Cited By ~ 424

Author(s):

Keyword(s):

Ischaemic Stroke ◽

Acute Ischaemic Stroke ◽

Controlled Trial ◽

Randomised Controlled